New Treatments for AML Remain Elusive, But Researchers Are UndeterredLauren M. Green
Meanwhile, there are still a large number of patients without sensitive driven mutations who are not available for TKI treatments [36]. Therefore, it is particularly important to find new therapeutic targets for NSCLC patients with different driven mutations or with TKI resistance. In recent years,...
These AML survival pathways are involved in drug resistance, evasion of the immune system, reprogramming metabolism, and impairing differentiation. In addition, based on the reports of enhanced clinical efficiencies when combining drugs or treatments, deeper investigation into possible pathways, which can...
Unfortunately, available Chokα inhibitors also have toxic side-effect and are not approved for use in patients. Hopefully, this research might encourage screening for safe drugs interfering with these pathways and contribute the development of new treatments for AITL....
From secondary metabolites to macromolecules, from cells to organs, these life components can be engineered and applied as new medical treatments. Being one of the key macromolecules, the messenger RNA (mRNA) also has the potential to be applied as new therapeutics. The concept of mRNA ...
“With all of the tools available to us today, as clinicians, we are really relying on cross-trial comparisons and safety cross-trial comparisons to guide our treatments. So, if we come back to the clinical dilemma that we all face today— what do we do with that [patient ...
Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise ...
This is an exciting time for the AL amyloidosis community as patient advocacy groups, academia, pharmaceutical companies, and regulatory agencies are joining in an effort to develop safe and effective treatments for patients with AL amyloidosis. ...
The Original Article was published on 19 October 2020 A strength of Evolving treatment patterns and outcomes in older AML: changing everything to change nothing? is documenting the suspected increasing use of non-intensive induction therapy in persons age ≥60 years from 1% 1999 to 2006 to 23%...
With advances in modern biotechnology, well-designed novel antibodies are finally paving the way for successful treatments of various cancers, including precise tumor immunotherapy, in the clinic. Antibody-based cancer therapy Introduction Over the past 30 years, therapeutic antibodies have revolutionized ...